Rodano, Italy

Mattia Bertolotti

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Mattia Bertolotti

Introduction

Mattia Bertolotti is a notable inventor based in Rodano, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the synthesis of complex compounds. With a total of 2 patents to his name, Bertolotti's work showcases his expertise and dedication to innovation.

Latest Patents

Bertolotti's latest patents include a method for the preparation of pimavanserin base. This process involves converting tert-butyl-N-[(4-propan-2-yloxyphenyl)methyl]carbamate to 1-(isocyanatomethyl)-4-propan-2-yloxybenzene, followed by the addition of N-[(4-fluorophenyl)methyl]-1-methylpiperidin-4-amine to yield pimavanserin base. The final step includes purifying the obtained compound to ensure high yield and purity. Another significant patent is an efficient method for the preparation of Cangrelor in salt form. This process includes the preparation and subsequent hydrolysis of an intermediate, leading to the final product.

Career Highlights

Bertolotti is currently employed at Olon S.p.a., where he continues to push the boundaries of pharmaceutical innovation. His work at Olon S.p.a. has allowed him to collaborate with other talented professionals in the field, further enhancing his contributions to the industry.

Collaborations

Some of his notable coworkers include Barbara Novo and Jacopo Bonanomi. Their collaborative efforts have played a crucial role in advancing the projects they work on together.

Conclusion

Mattia Bertolotti's innovative work in the pharmaceutical industry exemplifies the impact of dedicated inventors on modern medicine. His patents reflect a commitment to improving drug synthesis processes, which can lead to better therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…